Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

Elon Musk Says Neuralink Could Slash Risk From AI As Firm Prepares For First Human Trials

Sep 21, 2023 - forbes.com
Elon Musk's company, Neuralink, is preparing to launch its first in-human trials for brain implants that could restore lost functions to people with paralysis. Musk believes that these implants could also help protect humanity from the risks of artificial intelligence by allowing humans to interact with computers using their thoughts alone, thereby improving communication with AI and reducing the "civilizational risk" AI poses. The company has begun recruiting for its first human clinical trial, which will test the safety and functionality of the implants in people with paralysis.

However, Neuralink has faced allegations of animal cruelty, with claims that monkeys used to test the device died as a result of the brain chips. The company has denied these claims, with Musk stating that no monkey has died as a result of a Neuralink implant. The launch of the human trials follows years of optimistic predictions from Musk and comes as other companies, such as Blackrock Neurotech and Synchron, have already begun human trials of similar technology.

Key takeaways:

  • Elon Musk's company, Neuralink, is preparing to launch its first in-human trials for brain implants that could restore lost functions to people with paralysis and reduce the risk posed by artificial intelligence.
  • The implantable tech will allow humans to interact with computers using their thoughts alone and is expected to improve human-to-AI and human-to-human communication.
  • Neuralink has started recruitment for its first human clinical trial, targeting participants with quadriplegia due to cervical spinal cord injury or ALS. The trial is expected to take around six years to complete.
  • Neuralink has faced allegations of animal cruelty, with claims that monkeys used to test the device died as a result of the brain chips. The company has denied these claims.
View Full Article

Comments (0)

Be the first to comment!